<?xml version="1.0" encoding="UTF-8"?>
<p>At 28 days post-immunization, the piglets were challenged with PRV epidemic strain HB1201 via nasal route with a highly lethal dose of 10
 <sup>7</sup> TCID
 <sub>50</sub>. Following challenge, all piglets developed fever beginning at 2 dpc and reached the peak at 3–4 dpc with rectal temperatures as high as 40.0–42°C. The three immunized groups (Bartha-gC
 <sub>
  <italic>HB</italic>
 </sub>
 <sub>1201</sub>, Bartha-gD
 <sub>
  <italic>HB</italic>
 </sub>
 <sub>1201</sub>, and Bartha-K61) did not exhibit a statistically significant difference in temperature fluctuation. However, clinically, piglets in the Bartha-K61 group showed significant respiratory symptom, loss of appetite, depression, vomiting, convulsion, and ataxia. Moreover, two piglets showed significant CNS symptoms and died at 5 and 9 dpc, respectively (
 <xref ref-type="fig" rid="F5">Figure 5A</xref>). In contrast, all piglets in other two groups survived the challenge, and none showed any apparent CNS symptom throughout the study, suggesting that Bartha-gC
 <sub>
  <italic>HB</italic>
 </sub>
 <sub>1201</sub> and Bartha-gD
 <sub>
  <italic>HB</italic>
 </sub>
 <sub>1201</sub> induced protective immunity.
</p>
